Breaking Down Bausch & Lomb: 6 Analysts Share Their Views
Ratings for Bausch & Lomb (NYSE:BLCO) were provided by 6 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 0 | 1 | 5 | 0 | 0 |
| Last 30D | 0 | 0 | 3 | 0 | 0 |
| 1M Ago | 0 | 0 | 1 | 0 | 0 |
| 2M Ago | 0 | 0 | 1 | 0 | 0 |
| 3M Ago | 0 | 1 | 0 | 0 | 0 |
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $18.0, with a high estimate of $21.00 and a low estimate of $15.00. Observing a 13.71% increase, the current average has risen from the previous average price target of $15.83.
Decoding Analyst Ratings: A Detailed Look
A comprehensive examination of how financial experts perceive Bausch & Lomb is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Matt Miksic | Barclays | Raises | Equal-Weight | $20.00 | $17.00 |
| Tom Stephan | Stifel | Raises | Hold | $16.00 | $15.00 |
| Larry Biegelsen | Wells Fargo | Raises | Equal-Weight | $18.00 | $17.00 |
| Tom Stephan | Stifel | Raises | Hold | $15.00 | $14.00 |
| Vijay Kumar | Evercore ISI Group | Maintains | In-Line | $18.00 | $18.00 |
| Patrick Wood | Morgan Stanley | Raises | Overweight | $21.00 | $14.00 |
Key Insights:
- Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Bausch & Lomb. This insight gives a snapshot of analysts' perspectives on the current state of the company.
- Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Bausch & Lomb compared to the broader market.
- Price Targets: Understanding forecasts, analysts offer estimates for Bausch & Lomb's future value. Examining the current and prior targets provides insight into analysts' changing expectations.
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Bausch & Lomb's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
Stay up to date on Bausch & Lomb analyst ratings.
Delving into Bausch & Lomb's Background
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
Bausch & Lomb's Financial Performance
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Positive Revenue Trend: Examining Bausch & Lomb's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 7.11% as of 30 September, 2025, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Bausch & Lomb's net margin is impressive, surpassing industry averages. With a net margin of -2.19%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Bausch & Lomb's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -0.44%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Bausch & Lomb's ROA excels beyond industry benchmarks, reaching -0.2%. This signifies efficient management of assets and strong financial health.
Debt Management: Bausch & Lomb's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.77.
The Basics of Analyst Ratings
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.